Artak Tovmasyan, PharmD, PhD, is an associate professor in the Department of Neurobiology at Barrow Neurological Institute. He directs the pharmacokinetics core laboratory at the Ivy Brain Tumor Center.
Dr. Tovmasyan’s expertise includes pharmaceutical sciences and drug development, particularly in the field of neuro-oncology. He is a member of the American Association for Cancer Research, the Society for Neuro-Oncology, the Society for Redox Biology and Medicine, and the Society for Porphyrins and Phthalocyanines.
Dr. Tovmasyan earned his PharmD and PhD degrees from the Yerevan State Medical University School of Pharmacy in Armenia, where he also completed a residency in drug development. He completed a postdoctoral fellowship in the Department of Radiation Oncology, Division of Cancer Biology at Duke University Medical Center.
Dr. Tovmasyan’s work in the pharmacokinetics core laboratory involves evaluating drugs used in Phase 0 clinical trials for brain tumor patients. The results obtained in this state-of-the-art laboratory enable doctors to implement the most efficient brain tumor treatment regimens. The lab also provides services in the assessment and design of preclinical pharmacokinetics studies for experimental drugs, collection and processing of specimens, publishing guidance, and assistance with grant applications. Dr. Tovmasyan’s research interests also include medicinal chemistry in the design and development of agents that target the brain, particularly novel radio-modulators for brain tumor therapy.
- Postdoctoral Fellowship, Duke University Medical Center, Department of Radiation Oncology-Cancer Biology, 2009-2014
- PhD, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Pharmaceutical Sciences, 2008
- Residency, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Drug Development, 2004-2005
- Internship, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, Drug Development, 2003-2004
- PharmD, Yerevan State Medical University, School of Pharmacy, Department of Chemistry, 2003
- American Association of Cancer Research
- Society for Neuro-Oncology
- Society for Redox Biology and Medicine
- Society of Porphyrins and Phthalocyanines
- Young Investigator Award, 23rd Annual Meeting of Society for Redox Biology and Medicine, 2016
- Young Investigator Award, Duke Cancer Institute, National Cancer Institute Radiation Oncology and Imaging Program Annual Retreat, 2016
- Fellowship Award at Emory University School of Medicine, Society for Redox Biology and Medicine, 2014
- Nominee, National Comprehensive Cancer Network Young Investigator Award, Duke University, 2014
- Fellowship, Friedrich-Alexander University Erlangen-Nürnberg, Department of Bioinorganic Chemistry, 2013
- Fellowship, University of Bourgogne, Institute of Molecular Chemistry, 2008
- Best Oral Presentation, 4th Young Medics’ International Conference, Armenian Medical Association, 2007
- Graduate Research Support Program Award, National Foundation of Science and Advanced Technologies, US Civilian Research and Development Foundation, 2006
- Travel Grant, Yerevan State Medical University, 2006
- Best Oral Presentation, 3rd Young Medics’ International Conference, National Academy of Sciences, 2005
- Travel Grant, 3rd Young Medics’ International Conference, Young Medics’ Association, 2005
- Anselmo W, Branchetti E, Grau JB, Li G, Ayoub S, Lai EK, Rioux N, Tovmasyan A, Fortier JH, Sacks MS, Batinic-Haberle I, Hazen SL, Levy RJ, Ferrari G. Porphyrin-Based SOD Mimic MnTnBu OE -2-PyP5+ Inhibits Mechanisms of Aortic Valve Remodeling in Human and Murine Models of Aortic Valve Sclerosis. J Am Heart Assoc. 2018;7(20):e007861.
- Carballal S, Valez V, Alvarez-Paggi D, Tovmasyan A, Batinic-Haberle I, Ferrer-Sueta G, Murgida DH, Radi R. Manganese porphyrin redox state in endothelial cells: Resonance Raman studies and implications for antioxidant protection towards peroxynitrite. Free Radic Biol Med. 2018;126:379-392.
- Batinic-Haberle I, Tovmasyan A, Spasojevic I. Mn Porphyrin-Based Redox-Active Drugs: Differential Effects as Cancer Therapeutics and Protectors of Normal Tissue Against Oxidative Injury. Antioxid Redox Signal. 2018;29(16):1691-1724.
- Al-Mutairi R, Tovmasyan A, Batinic-Haberle I, Benov L. Sublethal Photodynamic Treatment Does Not Lead to Development of Resistance. Front Microbiol. 2018;9:1699.
- Sidlauskaite E, Gibson JW, Megson IL, Whitfield PD, Tovmasyan A, Batinic-Haberle I, Murphy MP, Moult PR, Cobley JN. Mitochondrial ROS cause motor deficits induced by synaptic inactivity: Implications for synapse pruning. Redox Biol. 2018;16:344-351.
- Cline JM, Dugan G, Bourland JD, Perry DL, Stitzel JD, Weaver AA, Jiang C, Tovmasyan A, Owzar K, Spasojevic I, Batinic-Haberle I, Vujaskovic Z. Post-Irradiation Treatment with a Superoxide Dismutase Mimic, MnTnHex-2-PyP5+, Mitigates Radiation Injury in the Lungs of Non-Human Primates after Whole-Thorax Exposure to Ionizing Radiation. Antioxidants. 2018;7(3):40.
- Tovmasyan A, Bueno-Janice JC, Jaramillo MC, Sampaio RS, Reboucas JS, Kyui N, Benov L, Deng B, Huang TT, Tome ME, Spasojevic I, Batinic-Haberle I. Radiation-Mediated Tumor Growth Inhibition Is Significantly Enhanced with Redox-Active Compounds That Cycle with Ascorbate. Antioxid Redox Signal. 2018;29(13):1196-1214.
- Charara M, Tovmasyan A, Batinic-Haberle I, Craik J, Benov L. Post-illumination cellular effects of photodynamic treatment. PLoS One. 2017;12(12):e0188535.